Clinical trial
Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1
NCT00032929 · National Institute on Drug Abuse (NIDA), NIH · Completed
Key facts
| NCT number | NCT00032929 |
|---|---|
| Title | Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 |
| Official title | Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence |
| Lead sponsor | National Institute on Drug Abuse (NIDA), NIH |
| Collaborators | Somerset Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cocaine-Related Disorders |
| Intervention type | Drug |
| Interventions | Selegiline |
| Enrollment | 269 |
| Start date | Mar 1, 2001 |
| Primary completion | Dec 1, 2002 |
| First posted | Apr 8, 2002 |
| Last update posted | Jan 12, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: